cetuximab Sep 8, 2021 Pfizer, Erasca Partner to Study Three-Drug Combo in BRAF V600E-Mutated Metastatic Colon Cancer Sep 20, 2020 Vectibix, Bavencio Show Activity as 'Rechallenge' Therapy Strategy in Metastatic Colorectal Cancer Premium Apr 9, 2020 FDA Approves Braftovi, Erbitux Combination for BRAF V600E-Mutated Colorectal Cancer Patients Nov 7, 2019 Colorectal Cancers Dial up Mutability in Response to Targeted Treatments Sep 24, 2019 Certain BRAF Mutations May Indicate Tumors More Likely to Respond to Anti-EGFR Therapy Premium Jul 9, 2019 BEACON Trial Reports Survival Benefit for Triple Targeted Treatment in BRAF-Mutated Metastatic CRC Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium Oct 4, 2017 BioMarker Strategies Wins NCI Grant to Develop Head and Neck Cancer CDx Dec 15, 2016 Prospective Study Supports Liquid Biopsy Monitoring of Colorectal Cancer Drug Response Premium May 13, 2016 Colorectal Cancer Patients' Cetuximab Response Can Be Discerned From FCGR2A Genotype Premium Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
